M1183 HCPCS Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS M1183: Immune Checkpoint Inhibitor Held, Steroids/Immunosuppressants Prescribed

HCPCS Level II code M1183 documents that an immune checkpoint inhibitor therapy was held and that corticosteroids or other immunosuppressants were prescribed or administered. The code is intended to capture clinician documentation of treatment interruption and initiation of immunosuppressive management for immune-related adverse events associated with checkpoint inhibitors. Nationally, this is important as use of immune checkpoint inhibitors expands across oncology, requiring clear documentation for care coordination, clinical decision-making, and payer review.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for M1183, common sites of service where it applies (inpatient, outpatient oncology clinics, and infusion centers), and the administrative role the code plays in documenting management of immune-related toxicities. The publication covers typical billing considerations, common modifiers used with this service, and how M1183 fits within oncology medication management workflows.

This summary provides national-level guidance on what M1183 represents, why accurate documentation matters for continuity of care and payer adjudication, and what topics the full publication addresses, including benchmarks, policy updates, and clinical context relevant to clinicians, coders, and payers. Data not available in the input will be identified in the full report.

AetnaBlue Cross Blue ShieldCignaUnitedHealthcareMedicareM1183HCPCS Level IIimmune checkpoint inhibitorimmunotherapycorticosteroidsimmunosuppressantsoncologymedication management

Billing Code Overview

HCPCS Level II code M1183 documents when immune checkpoint inhibitor therapy is held and corticosteroids or immunosuppressants are prescribed or administered. The code captures clinician documentation that treatment with an immune checkpoint inhibitor was temporarily suspended and that corticosteroid or other immunosuppressive therapy was initiated to manage immune-related adverse events.

Service type: Medication management and treatment interruption documentation related to immune therapy

Typical site of service: Hospital inpatient, outpatient oncology clinic, or infusion center where immune checkpoint inhibitors are administered and immune-related toxicities are managed

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with metastatic non–small cell lung cancer receiving an immune checkpoint inhibitor (e.g., anti–PD-1 therapy) presents to the oncology clinic with new grade 2–3 diarrhea and fatigue three weeks after infusion. The oncology clinician documents that the immune checkpoint inhibitor therapy is being held and prescribes oral corticosteroids (prednisone) with instructions for taper; the clinician also documents that additional immunosuppressive therapy (e.g., infliximab) may be required if symptoms worsen. Documentation is placed in the medical record noting the therapy hold, the steroid prescription and dosing, the plan for monitoring, and communication with the infusion center and primary oncologist. Typical workflow includes assessment of adverse event severity, verification of current infusion schedule, coordination with the infusion pharmacy to delay or cancel the next dose, prescription entry for corticosteroids or immunosuppressants, and follow-up scheduling. Typical site of service is an outpatient oncology clinic or infusion center; inpatient admission may occur if severe immune-related adverse events require IV corticosteroids or higher-level care. Service type is clinical documentation and care coordination related to immune checkpoint inhibitor therapy management, medication prescription, and treatment hold.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the documentation or management required to pause therapy and manage severe immune-related toxicity is substantially greater than typical and payer allows.

HCPCS M1272: Kidney or Kidney-Pancreas Transplant Waitlist Membership

HCPCS-M1437-TELEHEALTH-ENCOUNTER

HCPCS M1437: Encounters Conducted via Telehealth

HCPCS-M1264-AGE-75-OR-OLDER-AT-DIALYSIS-INITIATION

HCPCS M1264: Patients Age 75 or Older at Dialysis Initiation

HCPCS-M1190-KIDNEY-HEALTH-EVALUATION-DOCUMENTATION-MISSING

HCPCS Level II M1190: Documentation Missing for Kidney Health Evaluation

HCPCS-M1266-SNF-ADMISSION

HCPCS M1266: Skilled Nursing Facility Admission

HCPCS-M1423-OPTIMAL-UROLOGIC-CARE-MIPS-VALUE-PATHWAY

HCPCS M1423: Optimal Care for Urologic Conditions, MIPS Value Pathway

HCPCS-M1394-STAGES-1-3-BREAST-CANCER-ONCOLOGY-CARE

HCPCS M1394: Stages I–III Breast Cancer

HCPCS-LEVEL-II-M1356-PATIENTS-WHO-DIED-DURING-MEASUREMENT-PERIOD

HCPCS Level II M1356: Patients Who Died During the Measurement Period

HCPCS-M1405-PATIENTS-RECURRENCE-DISEASE-PROGRESSION

HCPCS M1405: Patients with Recurrence or Disease Progression

HCPCS-M1446-PATIENT-DEATH-DURING-MEASURE-PERIOD

HCPCS Level II M1446: Patient Death During Measure Assessment Period

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
207RC0000X	Medical Oncology	Primary specialty managing checkpoint inhibitor therapy and immune-related adverse events.
207RH0000X	Hematology-Oncology	Oncology subspecialists who manage systemic anticancer therapies.
363A00000X	Allergy & Immunology	Consulted for complex immune-related adverse events and immunosuppressive strategies.
208000000X	Internal Medicine	Hospitalists or internists involved when patients are admitted for severe toxicity.
261QR0205X	Pharmacy	Oncology pharmacists involved in prescription, dosing, and infusion coordination.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Lung cancer is a common indication for immune checkpoint inhibitor therapy.
`C80.1`	Malignant (primary) neoplasm, unspecified	Advanced malignancy where checkpoint inhibitors may be used and therapy management is required.
`D86.9`	Sarcoidosis, unspecified	Immune-related inflammatory conditions can mimic or complicate checkpoint inhibitor toxicity; used when relevant.
`K52.9`	Noninfective gastroenteritis and colitis, unspecified	Diarrhea/colitis is a common immune-related adverse event prompting steroid therapy and hold of checkpoint inhibitor.
`T88.7XXA`	Unspecified adverse effect of drug or medicament, initial encounter	Used when an immune-related adverse reaction to immunotherapy requires management and documentation.
`M79.1`	Myalgia	Musculoskeletal immune-related symptoms that may prompt therapy hold and steroid treatment.
`L40.0`	Psoriasis vulgaris	Exacerbation of autoimmune dermatologic conditions can occur with checkpoint inhibitors, requiring treatment and possible hold.
`G43.909`	Migraine, unspecified, not intractable, without status migrainosus	Neurologic symptoms attributable to immune-related effects that may require immunosuppression and documentation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Commonly used for the clinician visit documenting the therapy hold and prescribing steroids.
`96372`	Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)	Used if corticosteroids or immunosuppressants are administered by injection in clinic.
`96365`	Intravenous infusion, initial, up to 1 hour	Used for administration of IV corticosteroids when patient requires infusion after holding checkpoint inhibitor.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	May be used for administration of immune checkpoint inhibitors when given; documentation of hold affects subsequent claims.
`99499`	Unlisted evaluation and management service	Occasionally used for care coordination or services not described by standard E/M codes when payers require an alternate billing pathway.

OpenPayer